CD274 and non-Hodgkin lymphoma: The remarkable response in cHL and PMBCL is attributed to their unique genetic properties that include copy number alterations of 9p24.1, on which the PD-L1 gene resides.17, , –20 In contrast, lower response rates to single-agent checkpoint inhibitor therapy have been observed among most non-Hodgkin lymphomas (NHLs), multiple myeloma (MM), and leukemias, with ORRs of 3–33%.19,21, –23